Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA)

NSE:SUNPHARMA Income Statement

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Operating Revenue	520,413	484,969	438,857	386,545	334,981
Other Revenue	5,372	-	-	-	-
Revenue	525,784	484,969	438,857	386,545	334,981
Revenue Growth (YoY)	8.42%	10.51%	13.53%	15.39%	2.01%
Cost of Revenue	107,474	114,422	113,187	108,761	92,185
Gross Profit	418,311	370,547	325,670	277,784	242,796
Selling, General & Admin	99,731	95,025	83,549	73,544	69,042
Other Operating Expenses	167,718	144,755	123,779	101,331	88,678
Operating Expenses	293,203	265,345	232,613	196,223	178,520
Operating Income	125,108	105,202	93,058	81,560	64,276
Interest Expense	-2,314	-2,385	-1,720	-1,274	-1,414
Interest & Investment Income	-	11,262	5,310	7,687	4,672
Earnings From Equity Investments	-153.5	-384.1	-479	-165.4	-123.3
Currency Exchange Gain (Loss)	1,855	361.3	-1,261	1,540	236.5
Other Non Operating Income (Expenses)	19,650	1,571	756.5	735.9	2,895
EBT Excluding Unusual Items	144,146	115,627	95,664	90,084	70,542
Merger & Restructuring Charges	-	-232.1	-643.9	-563.5	-
Gain (Loss) on Sale of Investments	-	-102	-240.3	7.7	260
Gain (Loss) on Sale of Assets	-	-99.7	75.4	347.5	138.8
Asset Writedown	-	-1,564	-312.5	-2,179	-155.5
Legal Settlements	-	-	-	-1,563	-895.6
Other Unusual Items	-6,779	-3,219	-1,071	-41,657	-42,166
Pretax Income	137,368	110,495	93,605	44,648	27,870
Income Tax Expense	27,720	14,395	8,476	10,755	5,147
Earnings From Continuing Operations	109,648	96,100	85,129	33,893	22,724
Minority Interest in Earnings	-357.1	-336.5	-393.6	-1,166	6,315
Net Income	109,290	95,764	84,736	32,727	29,038
Net Income to Common	109,290	95,764	84,736	32,727	29,038
Net Income Growth	14.12%	13.01%	158.92%	12.70%	-22.87%
Shares Outstanding (Basic)	2,397	2,399	2,399	2,399	2,399
Shares Outstanding (Diluted)	2,397	2,399	2,399	2,399	2,399
Shares Change (YoY)	-0.11%	-	-	-	-
EPS (Basic)	45.60	39.91	35.32	13.64	12.10
EPS (Diluted)	45.60	39.90	35.30	13.60	12.10
EPS Growth	14.29%	13.03%	159.56%	12.40%	-22.89%
Free Cash Flow	119,435	99,332	28,738	74,895	50,002
Free Cash Flow Per Share	49.83	41.40	11.98	31.21	20.84
Dividend Per Share	16.000	13.500	11.500	10.000	7.500
Dividend Growth	18.52%	17.39%	15.00%	33.33%	87.50%
Gross Margin	79.56%	76.41%	74.21%	71.86%	72.48%
Operating Margin	23.79%	21.69%	21.20%	21.10%	19.19%
Profit Margin	20.79%	19.75%	19.31%	8.47%	8.67%
Free Cash Flow Margin	22.72%	20.48%	6.55%	19.38%	14.93%
EBITDA	150,862	128,760	116,513	101,536	83,451
EBITDA Margin	28.69%	26.55%	26.55%	26.27%	24.91%
D&A For EBITDA	25,754	23,559	23,456	19,975	19,175
EBIT	125,108	105,202	93,058	81,560	64,276
EBIT Margin	23.79%	21.69%	21.20%	21.10%	19.19%
Effective Tax Rate	20.18%	13.03%	9.05%	24.09%	18.47%
Revenue as Reported	545,435	498,510	445,202	395,760	343,337

Updated Jan 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.